Amgen stock has delivered a 75.2% return over the past five years, and the current valuation picture sits in a middle ground where the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market based multiples look roughly in line with peers.

• Over five years, a 75.2% total return suggests Amgen has already rewarded patient shareholders, so any further upside case now leans more on valuation support than on a low entry price.
• Future cash flow expectations from Amgen's drug portfolio can support the intrinsic value case, while ongoing requirements for research spending and potential competition in key therapies may limit how much of that value is ultimately realised.
• On Simply Wall St's broader checks, Amgen scores 3 out of 6 on valuation, which indicates a mixed picture rather than a clear bargain or a clearly expensive stock.

The issue now is whether Amgen's share price already reflects most of that intrinsic value estimate, or if the current discount still offers a margin of safety for new capital.

Is Amgen a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach values Amgen by projecting future cash flows and discounting them back to today. On this model, Amgen generated about $9.1b in free cash flow over the last twelve months, with assumptions that cash flows continue growing rather than shrinking. Plugging those projections into a 2 Stage Free Cash Flow to Equity framework leads to an estimated intrinsic value of about $685 per share.

Compared with the current share price, that DCF estimate implies the stock trades at roughly a 46.5% discount to its modeled worth. For investors, the key point is that Amgen’s valuation case here rests on sizeable, ongoing cash generation that the model assumes can be sustained over time rather than on aggressive speculative growth.

Based on these cash flow assumptions, Amgen stock appears undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Amgen is undervalued by 46.5%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Is Amgen Fairly Priced on Earnings?

P/E is a useful way to look at Amgen because earnings remain a key driver of how investors value established biopharma companies. Amgen trades on a P/E of about 25.3x, which is above the broader biotech industry average of 17.0x but below the peer average of 46.8x. This places the stock in a middle zone, not screened as a clear bargain but also not priced at the higher levels seen for some peers.

A fair P/E multiple for Amgen, based on its size, margins, industry and risk profile, is estimated at 25.3x, almost identical to where the stock currently trades. That close alignment suggests the market price is largely in line with what this framework would expect, given the available earnings data rather than implying a strong discount or premium.

On the P/E measure, Amgen appears roughly fairly valued relative to what its earnings profile would typically justify.

The Amgen Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Amgen's valuation puzzle leaves off, explaining what would need to happen to Amgen's growth, margins and earnings for the stock to be worth materially more or less than it is today. Rather than relying on a single multiple or model result, each narrative sets out the key assumptions behind its view of fair value so you can track those against Amgen's actual reported outcomes over time on the Community page.

Amgen investors in the community are split between a pipeline-led upside story and concern that the stock is already pricing in a best case obesity outcome.

Bull case: 15% undervalued

"The bullish analysts are assuming Amgen's revenue will grow by 6.5% annually over the next 3 years, and that profit margins will increase from 21.0% today to 29.6% in 3 years time…"

Bear case: roughly fairly valued

"MariTide's commercial ramp-up will take years post-launch, while Amgen’s high-margin legacy moats (Prolia and Enbrel) are already eroding at a brutal 30%+ year-over-year clip right now…"

Do you think there's more to the story for Amgen? Head over to our Community to see what others are saying!

The Bottom Line

For Amgen, the Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside, while the P/E view says the stock is priced about right relative to current earnings. That split comes down to how confident you are that Amgen can keep turning its pipeline and existing portfolio into sustained cash flows that match the intrinsic value assumptions. The broader checks look mixed rather than emphatically cheap, so the key question is whether the current discount to intrinsic value is compensation for real competitive and execution risks or a genuine opportunity if Amgen delivers on those cash flow expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.